cells

Etrumadenant

ETRUMADENANT (AB928): THE FIRST AND ONLY DUAL ADENOSINE RECEPTOR ANTAGONIST TARGETING A2aR AND A2bR

Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain anti-tumor interventions, such as chemotherapy and radiation.

The A2a/A2b receptors, expressed on the surface of immune cells, mediate the immunosuppressive effects of adenosine.

ETRUMADENANT CLINICAL TRIALS

Non-small cell lung cancer, PD-L1 positive (ARC-7)

A Phase 2 trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab + zimberelimab, and domvanalimab + zimberelimab + etrumadenant in front-line non-small cell lung cancer.

Non-small cell lung cancer, EGFRmut (ARC-4)

A Phase 1b trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant + carboplatin + pemetrexed ± zimberelimab in EGFR mutant non-squamous non-small cell lung cancer.

Castration-resistant prostate cancer (ARC-6)

A Phase 1b/2 trial to evaluate the efficacy and safety of etrumadenant-based treatment combinations in participants with metastatic castration-resistant prostate cancer.

Colorectal cancer (ARC-3)

A Phase 1b trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant + mFOLFOX in participants with gastroesophageal cancer or colorectal cancer.

Colorectal Cancer (ARC-9)

A randomized Phase 1b/2, open-label, multi-center platform study to evaluate the efficacy of etrumadenant (AB928)-based combinations in patients with metastatic colorectal cancer.